ODD Stock Recent News

ODDITY Tech (ODD) shares surge in Tuesday's extended hours trading session after the digital-first consumer brand lifted its full-year net revenue guidance while beating first quarter earnings estimates. ODDITY Tech Global CFO Lindsay Drucker Mann comes on Asking for a Trend with Josh Lipton and Julie Hyman to speak on the company's position in the beauty product space, its ability to scale its brands, and comments on the business' EBITDA margins.

Il Makiage owner Oddity Tech beat Wall Street's expectations on the top and bottom lines, leading it to raise its guidance. The rosy set of results comes as the retail industry braces for the negative impact tariffs will have on their businsses.

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- ODDITY Tech Ltd. (NASDAQ: ODD) today announced its financial results for the first quarter ended March 31, 2025.

Oddity's AI-driven, direct-to-consumer model ensures high profitability and efficiency, bypassing traditional retail channels and leveraging data for personalized customer experiences. The company's rapid growth, with a 40% CAGR since 2018, and strong margins highlight its superior operating model and innovative approach. Oddity's control over the customer journey and data collection drives high conversion rates, brand loyalty, and low product-return rates.

After reaching an important support level, Oddity Tech (ODD) could be a good stock pick from a technical perspective. ODD surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.

Oddity Tech (ODD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ODD broke through the 20-day moving average, which suggests a short-term bullish trend.

VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). H. Lundbeck A/S (Lundbeck) announced that amlenetug has received Orphan Drug Designation (ODD) from the MHLW in Japan.

Oddity Tech (ODD -0.53%) reported its fourth-quarter and full-year 2024 earnings on February 26, 2025, highlighting strong growth and investments in future expansion. The company is seeing growth through repeat sales and its direct-to-consumer business, with new brands on the horizon in 2025 and 2026.

Oddity Tech Ltd. (NASDAQ:ODD ) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Maria Lycouris - IR Oran Holtzman - Co-Founder and CEO Niv Price - CTO Lindsay Drucker Mann - Global CFO Conference Call Participants Cory Carpenter - JPMorgan Youssef Squali - Truist Securities Javier Escalante - Evercore ISI Andrew Boone - Citizens Dara Mohsenian - Morgan Stanley Scott Schoenhaus - KeyBanc Capital Markets Lorraine Hutchinson - Bank of America Lauren Lieberman - Barclays Operator Good morning.

Oddity Tech (ODD) came out with quarterly earnings of $0.20 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.17 per share a year ago.